MedPath

山西汾河制药有限公司

Ownership
-
Established
2003-12-24
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

79

NMPA:79

Drug Approvals

Gliclazide Tablets

Product Name
格列齐特片
Approval Number
国药准字H14020012
Approval Date
May 26, 2022
NMPA

Ofloxacin Tablets

Product Name
氧氟沙星片
Approval Number
国药准字H14020015
Approval Date
May 26, 2022
NMPA

Azithromycin Capsules

Product Name
阿奇霉素胶囊
Approval Number
国药准字H20066384
Approval Date
Jun 3, 2021
NMPA

Metformin Hydrochloride Tablets

Product Name
盐酸二甲双胍片
Approval Number
国药准字H14023737
Approval Date
Sep 4, 2020
NMPA

Telmisartan Capsules

Product Name
欣蕊
Approval Number
国药准字H20050380
Approval Date
Sep 4, 2020
NMPA

Compound Reserpine Tablets

Product Name
复方利血平片
Approval Number
国药准字H14023611
Approval Date
Sep 2, 2020
NMPA

Vitamin U, Belladonna and Aluminium Capsules

Product Name
维U颠茄铝胶囊
Approval Number
国药准字H14023863
Approval Date
Sep 2, 2020
NMPA

Grisefulvin Tablets

Product Name
灰黄霉素片
Approval Number
国药准字H14021848
Approval Date
Sep 1, 2020
NMPA

Alprazolam Tablets

Product Name
阿普唑仑片
Approval Number
国药准字H14021188
Approval Date
Sep 1, 2020
NMPA

Oleanolic Acid Tablets

Product Name
齐墩果酸片
Approval Number
国药准字H14021192
Approval Date
Sep 1, 2020
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 8
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.